Characterise viral vectors with precision using NanoSight Pro. Measure size, concentration, and aggregation to support gene therapy development.
Gene therapy is redefining the treatment of genetic and acquired diseases by enabling the targeted delivery of therapeutic DNA into cells. At the core of this approach are viral vectors such as adeno-associated virus and lentivirus, which act as highly engineered delivery systems designed to operate with precision at the nanoscale. Their effectiveness depends on accurate design, control, and characterisation throughout development.
The performance of viral vectors is intrinsically linked to their physical and biological properties. Parameters such as particle size, concentration, and aggregation behaviour directly influence dosing accuracy, transduction efficiency, and therapeutic outcomes. Even small variations in these attributes can have significant downstream effects on safety and efficacy.
However, viral vector systems are rarely uniform. Typical preparations contain a complex mixture of full capsids, empty or partially filled particles, aggregates, and process-related impurities. This heterogeneity introduces significant analytical challenges, particularly when subtle changes in particle populations can alter performance in ways that are not immediately visible.
Accurate and reproducible characterisation at the particle level is therefore essential. Without clear insight into viral vector populations, critical risks may remain hidden until later stages of development, when they are more costly and difficult to resolve.
With the NanoSight Pro you can:
✔ Detect subtle changes in viral vector populations early in development
✔ Quantify particle concentration and size with high precision
✔ Generate reproducible, particle-level data to support confident decisions
NanoSight Pro sets the benchmark for viral vector characterisation by delivering best-in-class nanoparticle tracking analysis with true particle-level resolution.
It enables researchers to move beyond averaged measurements and gain precise, actionable insight into complex viral systems. In a field where small variations have major implications, NanoSight Pro provides the clarity and confidence required to accelerate gene therapy development.
Works with OmniTrust: Malvern Panalytical's compliance solution for the regulated environment
The most critical risks in viral vector development rarely present as obvious failures. Instead, they arise as subtle, nanoscale variations in particle populations that directly influence efficacy, safety, and dose accuracy. Without the ability to resolve individual particles, these changes remain obscured within complex, heterogeneous samples, allowing critical issues to progress unnoticed.
These risks are inherently difficult to detect because they originate at the nanoscale, where even minor shifts in particle size, concentration, or distribution can have significant downstream effects.
Conventional analytical techniques typically rely on ensemble measurements, which average out particle behaviour and mask low-abundance sub-populations or early-stage aggregation. As a result, meaningful changes in vector quality are often only identified at later stages, when they are more difficult and costly to address.
NanoSight Pro overcomes these limitations by enabling direct, particle-by-particle analysis using nanoparticle tracking analysis. By simultaneously measuring size and concentration while visualising particles in real time, it provides the resolution needed to reveal hidden variability and emerging risks.
NanoSight Pro combines sensitivity, precision, and real-time insight to uncover what other techniques miss. By exposing critical risks early in development, it enables proactive decision-making, strengthens process control, and ensures more reliable therapeutic outcomes.
Viral vector systems are highly sensitive to changes in formulation, processing, and storage conditions. Subtle nanoscale variations such as slight increases in aggregation or shifts in particle size distribution can compromise stability, reduce transduction efficiency, or alter biodistribution. These effects often only become apparent during scale-up, long-term storage, or clinical application.
Without detailed insight into particle-level behaviour, these issues can remain hidden until they impact performance, leading to delays, increased costs, or regulatory challenges.
NanoSight Pro addresses this challenge through nanoparticle tracking analysis, enabling direct visualisation and measurement of individual viral particles in suspension. By providing early detection of changes in size, concentration, and aggregation, it supports more informed decision-making and reduces the risk of late-stage failure.
With its ability to deliver high-resolution, early-stage insight, NanoSight Pro sets the standard for proactive risk management in gene therapy development. By identifying critical changes before they escalate, it helps organisations avoid costly setbacks and maintain control as they scale.
Understanding the integrity of viral vector populations is essential for ensuring consistent performance. NanoSight Pro enables precise measurement of particle size distribution and concentration, allowing scientists to identify changes that may impact efficacy or safety.
By tracking individual particles rather than relying on ensemble averages, it provides a more accurate representation of complex viral samples. This level of detail is critical for identifying aggregation, distinguishing sub-populations, and monitoring process-induced variation.
With NanoSight Pro, you can:
✔ Measure viral particle concentration by size with high accuracy
✔ Detect aggregation and subtle shifts in particle populations
✔ Visualise individual particles to confirm sample integrity
NanoSight Pro redefines viral vector analysis by delivering best-in-class clarity at the individual particle level. This enables researchers to confidently assess sample integrity, detect early signs of change, and build stronger, more reliable data sets that support development and regulatory success.
Formulation and storage conditions play a critical role in maintaining viral vector stability. Small changes in buffer composition, temperature, or handling can influence aggregation behaviour and particle integrity.
NanoSight Pro allows researchers to evaluate how viral vectors respond to different conditions in real time. This enables the optimisation of formulations that preserve stability and performance throughout the product lifecycle.
With NanoSight Pro, you can:
✔ Assess the impact of formulation variables on particle stability
✔ Monitor aggregation behaviour under different storage conditions
✔ Support the development of robust and reproducible formulations
By delivering precise, real-time insight into particle behaviour, NanoSight Pro sets a new standard for formulation optimisation. Its best-in-class capabilities enable more stable products, more consistent performance, and greater confidence across the entire development lifecycle.
Viral vector preparations are inherently heterogeneous, containing multiple particle types that influence overall performance. Distinguishing these sub-populations is essential for improving product quality and consistency.
NanoSight Pro provides the resolution needed to characterise this complexity. By analysing particle-by-particle behaviour, it reveals variations that are often hidden by traditional techniques, enabling a deeper understanding of vector systems.
With NanoSight Pro, you can:
✔ Identify and differentiate heterogeneous particle populations
✔ Detect low-abundance sub-populations that impact performance
✔ Gain deeper insight into viral vector behaviour in solution
As a best-in-class platform, NanoSight Pro enables a level of insight that transforms how researchers understand viral vector systems. By fully resolving heterogeneity, it supports better control, improved quality, and more predictable therapeutic performance.
NanoSight Pro delivers the detailed, particle-level insight required to confidently characterise viral vectors throughout gene therapy development. By combining high-resolution measurement with intuitive analysis, it enables scientists to better understand complex systems and make more informed decisions at every stage.
This enhanced understanding supports improved process control, more robust formulations, and greater consistency between batches. It also strengthens analytical data packages, helping to meet regulatory expectations with confidence.
✔ Direct visualisation of individual viral particles in suspension
✔ Nanoparticle tracking analysis for high-resolution size measurement
✔ Accurate particle concentration measurement by size
✔ Detection of aggregation and subtle population changes
✔ Insight into heterogeneous and complex samples
✔ Support for formulation optimisation and stability studies
✔ Improved batch-to-batch consistency
✔ Enhanced process development and control
✔ Stronger analytical data for regulatory submissions
✔ Accelerated development timelines through early insight
NanoSight Pro is the definitive solution for viral vector characterisation. Combining precision, reproducibility, and depth of insight, it sets the industry standard for nanoparticle analysis in gene therapy. By turning nanoscale complexity into clear, actionable data, it empowers organisations to accelerate development, reduce risk, and achieve consistent, high-quality outcomes.
Measure protein size and detect aggregation to optimise stability and support biologic drug development.
Characterise nanoparticle size and surface charge to optimise delivery efficiency and stability.
Verify particle size and stability to maintain product quality and regulatory compliance.
Analyse vesicle size and aggregation to support emerging therapeutic applications.
Characterize protein stability, aggregation and molecular behaviour to ensure efficacy and shelf life.
Analyse particle size and stability of antigens and delivery systems for effective vaccine performance.
Measure viral vector size and stability to ensure safe and effective gene delivery.
Understand nanoparticle size and surface properties to control drug release and targeting.
Measure size, zeta potential and concentration using DLS and NTA. Detect instability early and optimise biologics with Zetasizer and NanoSight.